Pharmaceutical News

RSS

IDRI awarded grant extension of $3.4M for identifying new leads and drug targets for tuberculosis

IDRI's drug discovery efforts continue to grow with a recently awarded grant extension of $3.4 million from the Bill & Melinda Gates Foundation. The additional funding was awarded to Tanya Parish, Ph.D., IDRI's Vice President of Drug Discovery, and supplements an earlier grant awarded in 2010, for a total of $7.8 million.

25 Mar 2014

Doctor Trusted grants certification to IMS Supplements' Best Prostate Formula

Online health retailer IMS Supplements, Inc. has recently been approved to display a doctor's seal of approval, a major benefit granted by consumer protection service Doctor Trusted.

24 Mar 2014

Russian Ministry of Health approves Medivir's simeprevir for chronic hepatitis C genotype 1 infection

Medivir AB announced today that the Russian Ministry of Health has approved Sovriad (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adults with compensated liver disease (including cirrhosis) who are treatment naïve or who have failed previous interferon therapy (pegylated or non-pegylated) with or without ribavirin. Russia will be the first country within EMEA to gain access to simeprevir, which represents a significant advance in hepatitis C treatment.

24 Mar 2014

Taiho Pharmaceutical obtains approval in Japan for anticancer drug Lonsurf

Taiho Pharmaceutical Co., Ltd. (Tokyo, President: Masayuki Kobayashi) announced on March 24 that it has obtained approval in Japan from the Ministry of Health, Labour and Welfare to manufacture and market the oral combination anticancer drug "Lonsurf(R) combination tablet T15, T20" (nonproprietary names: trifluridine and tipiracil hydrochloride; development code: TAS-102), for the treatment of patients with unresectable advanced or recurrent colorectal cancer (only if refractory to standard therapies).

24 Mar 2014

FDA approves Xolair for treatment of chronic idiopathic urticaria

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria, a form of chronic hives.

24 Mar 2014

Otsuka obtains regulatory approval in Japan for pharmacological treatment of ADPKD

Otsuka Pharmaceutical Co., Ltd. today announced it has become the first company in the world to obtain regulatory approval for a pharmacological treatment of autosomal dominant polycystic kidney disease (ADPKD). Samsca (generic name: tolvaptan) has been approved in Japan in 7.5-mg and 15-mg tablet forms for extended use for the additional indication of ADPKD. Also, the new dosage form of 30-mg Samsca tablets has received approval for the indication of ADPKD.

24 Mar 2014

Researchers developing new medication to tackle river blindness and elephantiasis

Researchers are developing new drug treatments to tackle river blindness and elephantiasis, which affect up to 150 million people across the world.

24 Mar 2014

Study: Mood stabilizing drug may help prevent head and neck cancer

A new study indicates that a commonly used mood stabilizing drug may help prevent head and neck cancer. The study is published early online in Cancer, a peer-reviewed journal of the American Cancer Society.

24 Mar 2014

Investigators find group of drugs to treat heart attacks and cancer metastasis

Massachusetts General Hospital (MGH) investigators may have found a way to solve a problem that has plagued a group of drugs called ligand-mimicking integrin inhibitors, which have the potential to treat conditions ranging from heart attacks to cancer metastasis.

24 Mar 2014

Biogen Idec's ALPROLIX gets Health Canada approval for hemophilia B

Today Biogen Idec announced that Health Canada has approved ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B.

21 Mar 2014

Brazil's ANVISA approves Genzyme's Lemtrada for multiple sclerosis treatment

Genzyme, a Sanofi company, announced today that Brazil's national health surveillance agency, ANVISA, has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS) to slow or reverse the accumulation of physical disability and reduce the frequency of clinical exacerbations.

21 Mar 2014

ZL105 drug could potentially replace currently used anticancer drugs, study finds

A revolution in cancer treatment could soon be underway following a breakthrough that may lead to a dramatic improvement in cancer survival rates.

21 Mar 2014

New study provides first ever reliable data on antibiotic use in non-EU countries

A new study, published in The Lancet Infectious Diseases journal, provides the first ever reliable data on antibiotic use in non-European Union southern and eastern European countries and newly independent states.

20 Mar 2014

Investigational vaccine reduces number of tumors in mice with lung cancer

Researchers at UC Davis have found that the investigational cancer vaccine tecemotide, when administered with the chemotherapeutic cisplatin, boosted the immune response and reduced the number of tumors in mice with lung cancer.

20 Mar 2014

Daiichi Sankyo files NDA for development and marketing of Methylene Blue medicinal product in Japan

Provepharm, a French company specialized in the development of pharmaceutical applications, today announces that Daiichi Sankyo, Co. Ltd., a global pharmaceutical firm, has filed an NDA (New Drug Application) for the development and marketing of the injectable Methylene Blue medicinal product in Japan, made out of Provepharm’s Proveblue Methylene Blue active substance.

20 Mar 2014

Tamiflu cuts H1N1 pandemic deaths by 25%, shows study

Adults hospitalised with H1N1 influenza during the 2009–2010 pandemic were 25% less likely to die from the disease if they were given antiviral drugs called neuraminidase inhibitors (NAIs) such as Tamiflu, according to a large meta-analysis involving more than 29 000 patients from 38 countries, published in The Lancet Respiratory Medicine journal. The findings also indicate that treatment within 2 days of flu symptoms developing halved the risk of death compared with later treatment or no treatment.

20 Mar 2014

New drug for patients with leukaemia and lymphoma puts an end to chemotherapy

Patients with terminal forms of leukaemia and lymphoma who have run out of treatment options could soon benefit from a new drug, which not only puts an end to chemotherapy and has virtually no side effects but also improves a patient's life expectancy and quality of life.

20 Mar 2014

Trimethoprim is more effective against streptococci than expected, says research

The focus of his team was also on samples, in which the bacteria failed to respond to the agent. They discovered two types of resistance. "Spontaneous mutations can occur in the gene for dihydrofolate reductase rendering trimethoprim no longer able to attack the changed enzyme, which means it becomes ineffective," Nitsche-Schmitz explained.

20 Mar 2014

Scientists step in with new way to determine drug safety without using animals

As some countries and companies roll out new rules to limit animal testing in pharmaceutical products designed for people, scientists are stepping in with a new way to test therapeutic drug candidates and determine drug safety and drug interactions — without using animals.

19 Mar 2014

Non-academic contemporaries take brain stimulants more often than students

Three per cent of young men in Switzerland take cognitive enhancement drugs at least once each year. Students hope this consumption will improve their exam performance, while their non-academic contemporaries seek primarily to remain awake for longer.

19 Mar 2014

Pharmaceutical News

IDRI awarded grant extension of $3.4M for identifying new leads and drug targets for tuberculosis

Doctor Trusted grants certification to IMS Supplements' Best Prostate Formula

Russian Ministry of Health approves Medivir's simeprevir for chronic hepatitis C genotype 1 infection

Taiho Pharmaceutical obtains approval in Japan for anticancer drug Lonsurf

FDA approves Xolair for treatment of chronic idiopathic urticaria

Otsuka obtains regulatory approval in Japan for pharmacological treatment of ADPKD

Researchers developing new medication to tackle river blindness and elephantiasis

Study: Mood stabilizing drug may help prevent head and neck cancer

Investigators find group of drugs to treat heart attacks and cancer metastasis

Biogen Idec's ALPROLIX gets Health Canada approval for hemophilia B

Brazil's ANVISA approves Genzyme's Lemtrada for multiple sclerosis treatment

ZL105 drug could potentially replace currently used anticancer drugs, study finds

New study provides first ever reliable data on antibiotic use in non-EU countries

Investigational vaccine reduces number of tumors in mice with lung cancer

Daiichi Sankyo files NDA for development and marketing of Methylene Blue medicinal product in Japan

Tamiflu cuts H1N1 pandemic deaths by 25%, shows study

New drug for patients with leukaemia and lymphoma puts an end to chemotherapy

Trimethoprim is more effective against streptococci than expected, says research

Scientists step in with new way to determine drug safety without using animals

Non-academic contemporaries take brain stimulants more often than students

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News